

Investor Relations Brief

5

2026

May



Molecular Diagnostics: ESCMID Global 2026 Wrap-Up

Bioneer Wraps Up ESCMID Global 2026 — 300+ European KOLs Take Note of Its Next-Gen Diagnostic Platforms

- Showcased CE-IVDR-certified ExiStation™ FA 96 and IRON-qPCR™ to target the European market
- Platforms optimized for the global trends of “diagnostic stewardship” and lab efficiency
- Over 300 European KOLs visited the booth, showing strong interest — expanding the global supply network

Bioneer’s Molecular Diagnostics Division successfully showcased its innovative molecular diagnostic solutions at ESCMID Global 2026, the European Congress of Clinical Microbiology and Infectious Diseases, held in Munich, Germany, from April 18 to 21.

At the exhibition, Bioneer focused on its flagship diagnostic platforms, which recently received EU CE-IVDR certification. More than 300 key opinion leaders (KOLs) from across Europe visited the company’s booth for product demonstrations and consultations, demonstrating strong interest in Bioneer’s technologies.

Clearing Regulatory Hurdles: ExiStation™ FA 96 and IRON-qPCR™ Align with Key Diagnostic Trends

Bioneer highlighted its HIV-1 quantitative and respiratory assay kits for the high-throughput ExiStation™ FA 96 system, as well as its respiratory assay kit for the point-of-care IRON-qPCR™ device.

This year’s diagnostics sessions at ESCMID Global placed a strong emphasis on “diagnostic stewardship”—the optimization of clinical decision-making and diagnostic workflows—as well as data-driven laboratory efficiency.

ExiStation™ FA 96 aligns with these priorities by combining high-throughput testing with automated tube opening, helping reduce potential exposure risks for laboratory personnel while streamlining laboratory workflows. IRON-qPCR™, which simultaneously detects five respiratory viruses in approximately 40 minutes, also attracted interest from European clinicians as a rapid diagnostic solution that can support timely clinical decision-making.



Molecular Diagnostics: ESCMID Global 2026 Wrap-Up

Showcasing Readiness for the Next Pandemic and AMR

Alongside its booth, Bioneer presented its mid- to long-term vision aligned with "AMR & Stewardship," one of ESCMID 2026's key themes. To address the globally growing threat of carbapenem resistance, the company announced the launch of the IRON-qPCR™ CRE Kit (carbapenem-resistance gene detection), aiming to quickly meet field demand in the AMR market.

Bioneer held in-depth discussions with numerous European partners and hospital representatives on expanding its diagnostic network, and both sides agreed that a "two-track" strategy — combining high-throughput testing (ExiStation™ FA 96) with point-of-care diagnostics (IRON-qPCR™) — could play a major role in building public healthcare infrastructure.

A Bioneer official said, "As European diagnostic regulations tighten and the market begins separating the strong players from the weak, we clearly felt on-site just how much trust our early CE-IVDR certification gives global partners," adding, "We will use our network with the 300-plus key KOLs who visited our booth to accelerate our push into European and global public procurement markets."



Molecular Diagnostics: Platforms for Military & Public Health

Bioneer's Molecular Diagnostics Division said it showcased innovative molecular diagnostic platforms for next-generation pandemic response at the recent Korean Society of CBRN Defense conference. The company focused on presenting a "one-stop diagnostic solution" optimized for specialized settings such as military units and public health institutions, drawing strong attention from attendees.

The key devices on display were the point-of-care IRON-qPCR™ and the fully automated, high-throughput ExiStation™ FA 96. What stands out most is how they maximize both safety and efficiency. Conventional molecular diagnostics required testers to manually open sample tubes, creating infection risk and requiring special protective gear and negative-pressure facilities. Bioneer's ExiStation™ FA 96, by contrast, automates everything from sample loading to result analysis in a sealed environment, without requiring a negative-pressure room.

A Bioneer official explained, "Our biggest strength is being able to run mass testing safely even in ordinary settings without a negative-pressure room," adding, "Processing up to 94 tests within two hours makes it a game-changer for places needing rapid response, like military bases or airports."




Molecular Diagnostics: Platforms for Military & Public Health

Beyond simply exhibiting products, Bioneer also laid out its future direction. A highlight at the conference was its "rapid-response platform": if a new viral variant emerges, Bioneer can develop a detection reagent within two weeks and add it directly to existing kits. This gives the company a powerful tool to generate immediate revenue and lead the market even in an unforeseen pandemic.

At the event, Chan-Hyo Lee, Director of Bioneer's Molecular Diagnostics Research Institute, presented to military officials on "Next-Generation Molecular Diagnostic Platforms Preparing Military and Public Health for the Next Pandemic." He said, "Our next-generation platforms will set a new standard for pandemic response in military and public health settings," adding, "We will keep expanding our presence in domestic and international disease-control markets through continued technological innovation."

An attendee at the conference praised Bioneer's presentation, saying, "It lowers the barrier to molecular diagnostics even in rugged environments lacking dedicated medical facilities," and added, "Strong results are expected in global public procurement and defense markets going forward."



Molecular Diagnostics: Bioneer at KSLM 2026 Spring Symposium

Bioneer showcased its molecular diagnostic technology and product portfolio at the 2026 Spring Symposium of the Korean Society for Laboratory Medicine, held April 23–24, 2026.

Bioneer presented diagnostic solutions optimized for a range of testing environments, centered on ▲ExiStation™ 48, an automated system combining nucleic acid extraction and real-time PCR into a single workflow, and ▲IRON-qPCR™, a next-generation point-of-care multiplex system that can rapidly detect up to 40 pathogens.

ExiStation™ 48 drew particular attention for combining simplified test prep, ease of use, and consistent results through compatibility with premix kits. Designed to run reliably not only in large labs but also in small and mid-sized hospitals with limited infrastructure and staff, it was seen as a solution with broad reach — even for institutions looking to bring testing in-house.

IRON-qPCR™, which rapidly detects up to 40 pathogens within 30–40 minutes, drew strong interest as a solution that meets demand for rapid, near-point-of-care testing beyond the traditional central-lab model.

Numerous laboratory medicine specialists and lab staff visited Bioneer's booth for product consultations, giving positive feedback on workflow improvement and lab efficiency. The event reaffirmed growing demand for automated, simplified molecular diagnostic solutions amid staffing shortages and rising expectations for speed and accuracy.

A Bioneer official said, "This symposium let us directly confirm the need for speed, accuracy, and operational efficiency across different testing environments," adding, "We will keep expanding our reach to a wider range of institutions, including small and mid-sized hospitals, with a portfolio tailored to each lab setting."



Business Updates

Life Sciences: Promoting Lab Equipment at Analytica 2026

Bioneer exhibited a range of equipment and products for life science and bioengineering research at Analytica 2026, held March 24–27 at the Munich trade fair grounds in Bavaria, Germany, as part of the Korea Pavilion operated by the Korea Research Industry Association (RNDIA). Held every two years in Munich, Analytica is the world's largest trade fair for analytical and life science technology; this year drew about 1,000 exhibiting companies and roughly 30,000 visitors, and Bioneer welcomed visitors from about 40 countries.

On display were core Bioneer products including the automated nucleic acid extraction system ExiPrep™ 96 Lite, the eco-friendly extraction reagent EcoQprep™, and the ultra-fast real-time PCR system ExiCycler™ V5, which achieves a 10.0°C/second ramping rate. Bioneer also promoted its broader research lineup, from raw materials to reagents and equipment for biotech R&D — demonstrating both its technical excellence as an equipment maker and its breadth as a full-solution provider. EcoQprep™ and ExiCycler™ V5 in particular drew strong interest from global researchers and distributors as innovative products that combine sustainability with research efficiency.

The show fostered active exchanges with researchers across many fields, along with positive feedback and discussions on potential collaboration. Bioneer will continue pursuing R&D and international partnerships to share its technology vision with customers at home and abroad and further strengthen its position in the global life sciences market.



Business Updates

Life Sciences: At KSBB Spring Meeting & Symposium

Bioneer showcased its core equipment and products at the 2026 Korean Society for Biotechnology and Bioengineering (KSBB) Spring Meeting and International Symposium, held April 8–10 at the Yeosu Expo Convention Center. The event drew 40 exhibiting companies and about 2,000 researchers; Bioneer ran two dedicated booths and welcomed about 300 visitors.

The booth showcased Bioneer's integrated genetic analysis solution mapped to researchers' workflows — including ExiPrep™ 96 Lite, EcoQprep™, and the ExiCycler™ V5, which achieves a 10.0°C/second ramping rate. Researchers showed particular interest in the EcoQprep™ Kit and Magnetic Separation Rack, praising their fast binding speed and shorter reaction times. Inquiries about ExiProgen™ were also brisk, confirming new demand for automated protein expression and purification equipment, while ExiCycler™ V5 drew a positive response for its speed and precise temperature control.

Using the customer information gathered at the show, Bioneer's Science Division plans to follow up with mailings, product materials, and demo invitations to drive sales growth, expand customer touchpoints, and boost product awareness.



Business Updates

Life Sciences: At the Korean Chemical Society

Bioneer showcased equipment and products for life science and chemistry research at the 2026 Korean Chemical Society (KCS) Spring Meeting and International Symposium, held April 15–17 at the Jeju International Convention Center. The event marked the KCS's 80th anniversary and the American Chemical Society's (ACS) 150th anniversary, drawing about 2,000 leading scholars and researchers from Korea and abroad; Bioneer ran two booths and welcomed about 200 visitors.

Bioneer promoted the eco-friendly extraction reagent EcoQprep™, the automated extraction system ExiPrep™ 96 Lite, the ultra-fast real-time PCR system ExiCycler™ V5 (10.0°C/second ramping rate), and the cell-free protein expression and purification system ExiProgen™.

ExiProgen™ drew particular interest for its ability to dramatically cut research time in drug candidate and protein research, while ExiCycler™ V5 also received positive feedback for reducing experiment time and delivering precise temperature control.

At the opening ceremony marking the KCS's 80th anniversary, Chairman Han-Oh Park, who also serves as an advisor to the Society, delivered a congratulatory address on how Bioneer's technology is rooted in chemistry-based solutions and how the company plans to advance its technology using AI.



Business Updates

CosmeRNA: Strengthening D2C Business at Home and Abroad

Starting in April 2026, the CosmeRNA Division fully renewed its own online store to upgrade its platform and strengthen its D2C (direct-to-consumer) business at home and abroad. In Korea, a home-care promotion introduced structured 1-, 3-, and 6-month usage programs, while platform improvements enhanced both product understanding and ease of purchase.

The domestic "Spring Awakening Promotion" adjusted CosmeRNA's pricing and product mix to lower the barrier to purchase, and expanded its subscription model around Scalp Care Program bundles to boost customer touchpoints and convenience. New-member perks, including season-limited gifts, are also being used to enhance the user experience.

In global markets, the renewed online store streamlined the journey from product discovery to purchase. Real customer reviews and richer content improved product understanding, while the mobile experience was redesigned so shoppers can intuitively check pricing, perks, and reviews.


These updates can be viewed on the domestic store (<https://cosmerna.co.kr>) and the global store (<https://www.cosmerna.com>). CosmeRNA will keep strengthening its global D2C competitiveness through customer-centered operations and continue growing sales.

SCALP CARE FOR YOU AND YOURS

*Give the Gift of a
Healthy Scalp*

Limited-Time Offer · Until May 31

Select Your Gift



AceBiome: BNR17 Trial Shows Positive Muscle Results

AceBiome announced that its probiotic *Lactobacillus gasseri* BNR17 showed changes in physical function and body composition markers in a pilot human trial involving older adults.

The study is notable as foundational data for follow-up research, since it examined both declining physical performance and changing body composition seen in older adults. Muscle mass and body fat markers both shifted between the pre- and post-intake measurements, pointing to potential for further research on BNR17 in senior health management.

Published in the *Journal of Functional Foods and Health (FSBH)*, the 8-week study involved 46 adults aged 65–74 in Daejeon. Participants took BNRThin, containing AceBiome's BNR17 probiotic, once daily, and researchers compared physical performance (SPPB), muscle mass, body fat, and abdominal fat markers before and after intake.

Total SPPB scores, which reflect overall mobility and lower-body function, rose significantly from baseline. Muscle-related markers — lean body mass (LBM), soft tissue mass, and lower-body muscle mass — increased, while body-fat markers such as weight, body fat mass, BMI, obesity index, and visceral fat area decreased.

AceBiome said the results are meaningful as a human study examining both muscle maintenance and body fat management in older adults. However, since this was a single-arm, pre/post pilot study, further validation through a larger randomized controlled trial may be needed.

Food Supply Biomaterial Health, 2026, Mar 6(1):e1
<https://doi.org/10.52389/FSBH.2026.6.e1>
e1FSBH 2765-4689

FSBH Food Supplements and Biomaterials for Health

Original Article

Check for updates

Lactobacillus gasseri BNR17 Improves Muscle Function and Body Composition in Older Adults

Seul-Ah Kim ^{1,2}, Yu Mi Jo ^{1,2}, Chang Won Ahn ^{1,2}, Ji-Hyun Yun ^{1,2}

¹AceBiome Inc., Seoul, Korea

²R&D Center, AceBiome Inc., Daejeon, Korea

OPEN ACCESS

Received: Feb 11, 2026

Revised: Feb 23, 2026

Accepted: Mar 13, 2026

Published online: Mar 23, 2026

Correspondence:

Ji-Hyun Yun, PhD

R&D Center, AceBiome Inc., 17 Techno 4-ro,

Yuseong-gu, Daejeon 34012, Korea.

Email: jhyun@acebiome.com

© 2026 Health Functional Food Future Forum. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID IDs

Seul-Ah Kim <https://orcid.org/0009-0001-9901-6389>

Yu Mi Jo <https://orcid.org/0000-0002-8929-0870>

Chang Won Ahn <https://orcid.org/0009-0003-0145-5263>

Ji-Hyun Yun <https://orcid.org/0000-0002-9296-6279>

Funding

This work was supported by the Research Institute of Advanced Industrial Technology (RI-AIAT) with funding from Daejeon Metropolitan City in 2024 (2024-00-LP-0020-05).

This research was supported by AceBiome Inc.

<https://je-fsbh.org>

1/72

BNR17 Effect on Muscle and Fat Mass




Fig. 1. Effects of *Lactobacillus gasseri* BNR17 on SPPB scores in the elderly. A total of 46 participants (23 men and 23 women) received oral supplementation with the probiotic *L. gasseri* BNR17 in the form of BNRThin[®] capsules (two capsules once daily) for 8 weeks, providing a total dose of 1×10^{10} colony-forming unit/day. SPPB was assessed before and after the 8-week intervention and consisted of three performance tests: standing balance (B), walking speed (C), and repeated chair stands (D). The total SPPB score (A) was calculated as the sum of the scores from the three tests. Values are expressed as mean $\pm$ standard deviation ($n = 46$). SPPB = Short Physical Performance Battery, ns = not significant.

* $p < 0.05$.




Fig. 2. Changes in grip strength before and after the 8-week *Lactobacillus gasseri* BNR17 intervention in the elderly. The experimental details were the same as in Fig. 1. Values are expressed as mean $\pm$ standard deviation ($n = 46$). ns = not significant.

total skeletal muscle mass in the human body and therefore changes in leg muscle mass may be more sensitively reflected in body composition analyses. It should be noted that BIA estimates muscle mass indirectly and may be influenced by factors such as hydration

<https://je-fsbh.org>

<https://doi.org/10.52389/FSBH.2026.6.e1>

6/72


AceBiome: AnaParactin Sponsors 2026 MBN Sunset Marathon

AceBiome served as an official sponsor of the 2026 MBN Sunset Marathon, held on the 11th at Seaside Park (Songsan Park) on Yeongjong Island. Through the sponsorship, the company introduced AnaParactin, its "take, apply, and wear" joint care brand, and gave every participant its newly launched AnaParactin Patch, letting runners experience the brand firsthand.

Run as a sunset-start race, the event featured half-marathon, 10K, and 3K kids' courses, drawing a wide range of participants from competitive runners to families. The event strengthened AnaParactin's association with active lifestyles like running and expanded its consumer touchpoints.

The AnaParactin Patch uses stretchable sports fabric, a patented TPE gel, and a breathable structure to stay securely in place on high-movement areas. Its menthol and lavender scent deliver a quick, gentle cooling sensation, making it easy to apply wherever everyday discomfort is felt.

With the supplement Joint AnaParactin, the topical AnaParactin Balm, and now the AnaParactin Patch, AceBiome has built out a joint care lineup that lets consumers choose the format that best fits their lifestyle and preferences.



AceBiome: BNRThin Wins Korea Healthcare Award, 5th Year

On the 15th, AceBiome won the grand prize in the dietary supplements/probiotics category at the 2026 Korea Medical Healthcare Awards, selected by the Chosun Ilbo. The awards recognize companies and brands that have contributed to healthcare industry growth and consumer health, and this win reflects the brand strength AceBiome has built in functional probiotics.

This marks the company's fifth year winning the category — in 2021–2022, 2024–2025, and now 2026 — continuing the track record its flagship brand BNRThin has built in functional probiotics.

BNRThin, built around *Lactobacillus gasseri* BNR17 — a probiotic strain isolated from Korean breast milk — is designed to support both body fat reduction and gut health. As the first probiotic strain recognized by Korea's Ministry of Food and Drug Safety for body-fat-reduction functionality, BNR17 has helped establish BNRThin as a leading brand in the functional probiotics market.

The award reflects the combined results of ingredient strength, product planning, R&D, and brand management. AceBiome has built a distinct position for BNRThin in the functional probiotics market and plans to keep offering consumers sustainable health solutions built on the brand's differentiated value.



AceBiome: BNRThin & BNR Queen No.1 in Loyalty, 4th Year

AceBiome's flagship probiotic brands BNRThin and BNR Queen ranked No. 1 in the diet-probiotics and menopause-probiotics categories, respectively, at the 2026 Brand Customer Loyalty Awards hosted by the Korea Consumer Forum — their fourth consecutive year winning. The evaluation, based on Brand Keys' Brand Customer Loyalty Index (BCLI) model, drew on a domestic consumer survey conducted March 9–22, 2026, with 388,853 respondents and 1,960,273 total responses.

The results show both brands maintaining consistently strong performance on key consumer-experience metrics — trust, attachment, repurchase intent, willingness to recommend, and resistance to switching. Both BNRThin and BNR Queen outperformed competing brands in their categories, sustaining solid consumer loyalty.

BNRThin is built on *Lactobacillus gasseri* BNR17, an individually approved probiotic strain recognized by Korea's Ministry of Food and Drug Safety for body-fat-reduction functionality, with product strength backed by human trials and academic research. The BNR17 product line has recorded cumulative sales of KRW 1 trillion and 20 million units sold as of 2025. BNR Queen combines BNR17 with *Sophora japonica* fruit extract and vitamins D, A, zinc, and selenium in a women-focused formula, expanding its market by addressing women's health needs across life stages.

The awards reaffirmed the market competitiveness of AceBiome's key brands in body-fat reduction and women's health. The company plans to keep strengthening brand competitiveness through science-based product development and a life-stage-tailored portfolio.

